# A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma

> **NCT02029430** · PHASE2 · COMPLETED · sponsor: **ImmunityBio, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Kaposi's Sarcoma
- HIV Positive
- AIDS

## Interventions

- **DRUG:** 50 mg/m2 aldoxorubicin
- **DRUG:** 100 mg/m2 aldoxorubicin
- **DRUG:** 150 mg/m2 aldoxorubicin

## Key facts

- **NCT ID:** NCT02029430
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-03
- **Primary completion:** 2016-04-25
- **Final completion:** 2016-04-25
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02029430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02029430, "A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02029430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*